Validating Antibodies for Research Applications in IHC
The importance of building a validation structure within your lab cannot be overstated. Once in place, the ability to identify high-quality specific results compared to spurious, non-specific antibody staining on tissue will be easier and allow the researcher to focus on downstream applications, such as single and multiplex IHC. This webinar will focus on the steps and challenges in antibody selection and validation to enable success and reproducibility in antibody staining in IHC .
Learning Objectives
- How to select and validate antibodies for research applications in IHC
- Understand the reagents and tools available today to support the validation of antibodies for research applications in IHC
About the presenters
Will Howat joined Abcam in August 2018 and is responsible for leading the global Imaging and Immunohistochemistry team. Prior to joining Abcam, he worked at AstraZeneca as the Team Leader of the Molecular Pathology Group, where his team developed biomarker assays for preclinical, Phase 1 and Phase 2 clinical trials. Before that he was at the Cancer Research UK Cambridge Institute where he set up and ran the Histopathology/ISH core facility for 9 years. He has also worked at the Wellcome Sanger Institute on the Atlas of Protein Expression and was responsible for the R&D for the Immunohistochemistry group. Will has a BSc (Hons) in Immunology & Pharmacology from the University of Strathclyde and a PhD in Pathology from the University of Southampton. He has first-author publications in the Lancet, American Journal of Pathology and Journal of Pathology as well as co-authored publications in Nature, Science, Nature Genetics, and Journal of Experimental Medicine.
Damian is the Global Product Manager for the clinical and research BOND systems and is based in Melbourne, Australia. Damian joined Leica Biosystems as a Scientist in 2007 working on the development of BOND-III. Throughout his career at Leica Biosystems he has held numerous roles working across the broad portfolio of Leica Biosystems products, included spending 7 years based out of the Newcastle UK site before returning to Australia in 2018.
Related Content
El contenido de Leica Biosystems Knowledge Pathway está sujeto a las condiciones de uso del sitio web de Leica Biosystems, disponibles en: Aviso legal.. El contenido, incluidos los webinars o seminarios web, los recursos de formación y los materiales relacionados, está destinado a proporcionar información general sobre temas concretos de interés para los profesionales de la salud y no está destinado a ser, ni debe interpretarse como asesoramiento médico, normativo o jurídico. Los puntos de vista y opiniones expresados en cualquier contenido de terceros reflejan los puntos de vista y opiniones personales de los ponentes/autores y no representan ni reflejan necesariamente los puntos de vista ni opiniones de Leica Biosystems, sus empleados o sus agentes. Cualquier enlace incluido en el contenido que proporcione acceso a recursos o contenido de terceros se proporciona únicamente por comodidad.
Para el uso de cualquier producto, debe consultarse la documentación correspondiente del producto, incluidas las guías de información, los prospectos y los manuales de funcionamiento.
Copyright © 2024 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.